{
 "disease": "mantle-cell-lymphoma",
 "label": "Mantle cell lymphoma",
 "url": "https://usebiotransfer.org/disease/mantle-cell-lymphoma/",
 "built": "2026-09-16",
 "facts_hash": {
  "answers": "8016e6d523c0",
  "targets": "0d628fb53ee6"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-16",
  "trials": "2026-09-16"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "CCND1",
   "ensembl": "ENSG00000110092",
   "n_drug_entries": 2,
   "n_distinct_drugs": 2,
   "drugs": {
    "BRICICLIB": "PHASE_1",
    "PALBOCICLIB": "APPROVAL"
   },
   "approved": [
    "PALBOCICLIB"
   ],
   "n_approved": 1,
   "approved_for": {
    "PALBOCICLIB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "BTK",
   "ensembl": "ENSG00000010671",
   "n_drug_entries": 24,
   "n_distinct_drugs": 20,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "ACALABRUTINIB": "APPROVAL",
    "BMS-986142": "PHASE_2",
    "BRANEBRUTINIB": "PHASE_2",
    "EDRALBRUTINIB": "PHASE_2",
    "ELSUBRUTINIB": "PHASE_2",
    "EVOBRUTINIB": "PHASE_3",
    "FENEBRUTINIB": "PHASE_3",
    "IBRUTINIB": "APPROVAL",
    "MSC-2364447": "PHASE_1",
    "ORELABRUTINIB": "APPROVAL",
    "PIRTOBRUTINIB": "APPROVAL",
    "POSELTINIB": "PHASE_2",
    "RILZABRUTINIB": "APPROVAL",
    "RITLECITINIB": "APPROVAL",
    "SPEBRUTINIB": "PHASE_2",
    "TIRABRUTINIB": "APPROVAL",
    "TOLEBRUTINIB": "PREAPPROVAL",
    "VECABRUTINIB": "PHASE_1_2",
    "ZANUBRUTINIB": "APPROVAL"
   },
   "approved": [
    "ACALABRUTINIB",
    "IBRUTINIB",
    "ORELABRUTINIB",
    "PIRTOBRUTINIB",
    "RILZABRUTINIB",
    "RITLECITINIB",
    "TIRABRUTINIB",
    "ZANUBRUTINIB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ACALABRUTINIB": [
     "B-cell chronic lymphocytic leukemia",
     "childhood leukemia",
     "mantle cell lymphoma"
    ],
    "IBRUTINIB": [
     "macroglobulinemia",
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "ORELABRUTINIB": [],
    "PIRTOBRUTINIB": [
     "mantle cell lymphoma",
     "non-Hodgkin lymphoma"
    ],
    "RILZABRUTINIB": [
     "autoimmune thrombocytopenic purpura"
    ],
    "RITLECITINIB": [
     "alopecia areata"
    ],
    "TIRABRUTINIB": [],
    "ZANUBRUTINIB": [
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia",
     "lymphoplasmacytic lymphoma",
     "Waldenstrom macroglobulinemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "SOX11",
   "ensembl": "ENSG00000176887",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "ATM",
   "ensembl": "ENSG00000149311",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "NSD2",
   "ensembl": "ENSG00000109685",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "BCL2",
   "ensembl": "ENSG00000171791",
   "n_drug_entries": 7,
   "n_distinct_drugs": 5,
   "drugs": {
    "APG-2575": "PHASE_3",
    "NAVITOCLAX": "APPROVAL",
    "OBATOCLAX": "PHASE_3",
    "OBLIMERSEN": "APPROVAL",
    "VENETOCLAX": "APPROVAL"
   },
   "approved": [
    "NAVITOCLAX",
    "OBLIMERSEN",
    "VENETOCLAX"
   ],
   "n_approved": 3,
   "approved_for": {
    "NAVITOCLAX": [],
    "OBLIMERSEN": [],
    "VENETOCLAX": [
     "B-cell chronic lymphocytic leukemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CD19",
   "ensembl": "ENSG00000177455",
   "n_drug_entries": 14,
   "n_distinct_drugs": 14,
   "drugs": {
    "AXICABTAGENE CILOLEUCEL": "APPROVAL",
    "BLINATUMOMAB": "APPROVAL",
    "BREXUCABTAGENE AUTOLEUCEL": "APPROVAL",
    "COLTUXIMAB RAVTANSINE": "PHASE_2",
    "DENINTUZUMAB MAFODOTIN": "PHASE_2",
    "INEBILIZUMAB": "APPROVAL",
    "LISOCABTAGENE MARALEUCEL": "APPROVAL",
    "LONCASTUXIMAB TESIRINE": "APPROVAL",
    "MDX-1342": "PHASE_2",
    "OBECABTAGENE AUTOLEUCEL": "APPROVAL",
    "OBEXELIMAB": "PHASE_3",
    "ONCOLYSIN B": "PHASE_2",
    "TAFASITAMAB": "APPROVAL",
    "TISAGENLECLEUCEL": "APPROVAL"
   },
   "approved": [
    "AXICABTAGENE CILOLEUCEL",
    "BLINATUMOMAB",
    "BREXUCABTAGENE AUTOLEUCEL",
    "INEBILIZUMAB",
    "LISOCABTAGENE MARALEUCEL",
    "LONCASTUXIMAB TESIRINE",
    "OBECABTAGENE AUTOLEUCEL",
    "TAFASITAMAB",
    "TISAGENLECLEUCEL"
   ],
   "n_approved": 9,
   "approved_for": {
    "AXICABTAGENE CILOLEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma"
    ],
    "BLINATUMOMAB": [
     "acute lymphoblastic leukemia",
     "B-cell acute lymphoblastic leukemia",
     "lymphoid leukemia"
    ],
    "BREXUCABTAGENE AUTOLEUCEL": [
     "mantle cell lymphoma"
    ],
    "INEBILIZUMAB": [
     "neuromyelitis optica"
    ],
    "LISOCABTAGENE MARALEUCEL": [
     "diffuse large B-cell lymphoma",
     "follicular lymphoma",
     "neoplasm of mediastinum"
    ],
    "LONCASTUXIMAB TESIRINE": [
     "diffuse large B-cell lymphoma",
     "B-cell neoplasm",
     "B-cell non-Hodgkin lymphoma"
    ],
    "OBECABTAGENE AUTOLEUCEL": [
     "B-cell acute lymphoblastic leukemia"
    ],
    "TAFASITAMAB": [
     "diffuse large B-cell lymphoma",
     "lymphoma"
    ],
    "TISAGENLECLEUCEL": [
     "diffuse large B-cell lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "MS4A1",
   "ensembl": "ENSG00000156738",
   "n_drug_entries": 18,
   "n_distinct_drugs": 18,
   "drugs": {
    "EPCORITAMAB": "APPROVAL",
    "FBT-A05": "PHASE_1_2",
    "GLOFITAMAB": "APPROVAL",
    "LFB-R603": "PHASE_1",
    "MOSUNETUZUMAB": "APPROVAL",
    "MT-3724": "PHASE_2",
    "OBINUTUZUMAB": "APPROVAL",
    "OCARATUZUMAB": "PHASE_2",
    "OCRELIZUMAB": "APPROVAL",
    "ODRONEXTAMAB": "APPROVAL",
    "OFATUMUMAB": "APPROVAL",
    "RITUXIMAB": "APPROVAL",
    "TOSITUMOMAB": "APPROVAL",
    "TOSITUMOMAB 131I": "PHASE_3",
    "TRU-015": "PHASE_2",
    "UBLITUXIMAB": "APPROVAL",
    "VELTUZUMAB": "PHASE_2",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": "APPROVAL"
   },
   "approved": [
    "EPCORITAMAB",
    "GLOFITAMAB",
    "MOSUNETUZUMAB",
    "OBINUTUZUMAB",
    "OCRELIZUMAB",
    "ODRONEXTAMAB",
    "OFATUMUMAB",
    "RITUXIMAB",
    "TOSITUMOMAB",
    "UBLITUXIMAB",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN"
   ],
   "n_approved": 11,
   "approved_for": {
    "EPCORITAMAB": [
     "follicular lymphoma",
     "B-cell non-Hodgkin lymphoma",
     "diffuse large B-cell lymphoma"
    ],
    "GLOFITAMAB": [
     "diffuse large B-cell lymphoma"
    ],
    "MOSUNETUZUMAB": [
     "follicular lymphoma"
    ],
    "OBINUTUZUMAB": [
     "follicular lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "OCRELIZUMAB": [
     "multiple sclerosis",
     "diffuse large B-cell lymphoma",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "ODRONEXTAMAB": [
     "follicular lymphoma"
    ],
    "OFATUMUMAB": [
     "relapsing-remitting multiple sclerosis",
     "B-cell chronic lymphocytic leukemia",
     "multiple sclerosis",
     "secondary progressive multiple sclerosis"
    ],
    "RITUXIMAB": [
     "non-Hodgkin lymphoma",
     "granulomatosis with polyangiitis",
     "B-cell chronic lymphocytic leukemia",
     "acute lymphoblastic leukemia",
     "rheumatoid arthritis",
     "microscopic polyangiitis",
     "pemphigus",
     "vasculitis"
    ],
    "TOSITUMOMAB": [
     "non-Hodgkin lymphoma"
    ],
    "UBLITUXIMAB": [
     "multiple sclerosis",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": [
     "follicular lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "NOTCH1",
   "ensembl": "ENSG00000148400",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BRONTICTUZUMAB": "PHASE_1"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "BTK": {
    "n": 189,
    "n_observational": 17,
    "n_active": 105,
    "n_withdrawn": 8,
    "trials": [
     {
      "nct": "NCT01804686",
      "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04484012",
      "title": "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855695",
      "title": "Avo In R/R And Previously Untreated MCL",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05006716",
      "title": "A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05294731",
      "title": "Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05529069",
      "title": "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05602363",
      "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05635162",
      "title": "Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643235",
      "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05780034",
      "title": "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05833763",
      "title": "A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.",
      "status": "RECRUITING",
      "last_update": "2024-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05976763",
      "title": "Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05990465",
      "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06029309",
      "title": "Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054776",
      "title": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136351",
      "title": "A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252675",
      "title": "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06263491",
      "title": "Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06341556",
      "title": "A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06357676",
      "title": "Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06363994",
      "title": "A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL",
      "status": "RECRUITING",
      "last_update": "2024-12-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482684",
      "title": "CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496308",
      "title": "Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2024-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06553872",
      "title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06564038",
      "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06572618",
      "title": "Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06675123",
      "title": "Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06697184",
      "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742996",
      "title": "A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06839053",
      "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846489",
      "title": "Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854003",
      "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Na\u00efve Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07029737",
      "title": "A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07199296",
      "title": "Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07257510",
      "title": "Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07261163",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07272499",
      "title": "Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07285590",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07341191",
      "title": "Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07377578",
      "title": "A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07460362",
      "title": "Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07609862",
      "title": "A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07673367",
      "title": "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07719556",
      "title": "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Na\u00efve Mantle Cell Lymphoma (MCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849654",
      "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01109069",
      "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01236391",
      "title": "Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2015-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599949",
      "title": "A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy",
      "status": "COMPLETED",
      "last_update": "2016-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01646021",
      "title": "Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2018-01-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776840",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01799889",
      "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01880567",
      "title": "Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02013128",
      "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "status": "TERMINATED",
      "last_update": "2015-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159755",
      "title": "Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02169180",
      "title": "Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213926",
      "title": "An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02242097",
      "title": "Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02268851",
      "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02269085",
      "title": "Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02303392",
      "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02328014",
      "title": "Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-12-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02356458",
      "title": "Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02362035",
      "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381080",
      "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",
      "status": "COMPLETED",
      "last_update": "2017-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419560",
      "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL",
      "status": "COMPLETED",
      "last_update": "2022-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02427620",
      "title": "Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446236",
      "title": "Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02455297",
      "title": "Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "TERMINATED",
      "last_update": "2017-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460276",
      "title": "A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02471391",
      "title": "ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)",
      "status": "UNKNOWN",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02558816",
      "title": "A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02682641",
      "title": "Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717624",
      "title": "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02733042",
      "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02735876",
      "title": "A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736617",
      "title": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02743546",
      "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02756247",
      "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858258",
      "title": "ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02869633",
      "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02927964",
      "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02972840",
      "title": "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02991638",
      "title": "Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers",
      "status": "UNKNOWN",
      "last_update": "2018-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088878",
      "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03112174",
      "title": "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03153202",
      "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190330",
      "title": "A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03206970",
      "title": "Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03219047",
      "title": "Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03232307",
      "title": "Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2019-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03235544",
      "title": "A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor",
      "status": "COMPLETED",
      "last_update": "2025-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03282396",
      "title": "Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03295240",
      "title": "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323151",
      "title": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03440567",
      "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03478514",
      "title": "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03617484",
      "title": "Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03623373",
      "title": "Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03710772",
      "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03824483",
      "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03836768",
      "title": "BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03863184",
      "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03877055",
      "title": "A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03891355",
      "title": "Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL",
      "status": "UNKNOWN",
      "last_update": "2022-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03932331",
      "title": "Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03939182",
      "title": "Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03946878",
      "title": "Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04002297",
      "title": "A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043845",
      "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04047797",
      "title": "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04115631",
      "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172246",
      "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189757",
      "title": "Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234061",
      "title": "Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282018",
      "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04402138",
      "title": "Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04477486",
      "title": "Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04564040",
      "title": "A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04566887",
      "title": "Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04624958",
      "title": "Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626791",
      "title": "Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04662255",
      "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665115",
      "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)",
      "status": "WITHDRAWN",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04716075",
      "title": "Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)",
      "status": "COMPLETED",
      "last_update": "2025-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736914",
      "title": "Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04765111",
      "title": "Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04783415",
      "title": "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802590",
      "title": "Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04849416",
      "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04880434",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913103",
      "title": "Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2021-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04930536",
      "title": "Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004064",
      "title": "Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05020392",
      "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "status": "COMPLETED",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05051891",
      "title": "A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-na\u0457ve Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076097",
      "title": "A Study of OLR in First-line Treatment of Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097443",
      "title": "Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05164770",
      "title": "Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-12-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176691",
      "title": "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05214183",
      "title": "Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249959",
      "title": "Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05431179",
      "title": "A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-04-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05458297",
      "title": "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05495464",
      "title": "A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05504603",
      "title": "Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564052",
      "title": "A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05716087",
      "title": "A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05788289",
      "title": "A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864742",
      "title": "Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (\u00b1 Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05951959",
      "title": "A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05978739",
      "title": "Evaluating Different Doses of Orelabrutinib in MCL",
      "status": "COMPLETED",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06192888",
      "title": "A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06255704",
      "title": "A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427213",
      "title": "This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504199",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522386",
      "title": "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06656221",
      "title": "A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07206264",
      "title": "Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07207785",
      "title": "PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07264894",
      "title": "ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548255",
      "title": "The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07592481",
      "title": "Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07684950",
      "title": "Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07784101",
      "title": "A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07799220",
      "title": "A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 0,
     "n_active": 5,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04484012",
       "title": "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-11-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05990465",
       "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06482684",
       "title": "CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2024-07-01",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07341191",
       "title": "Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07673367",
       "title": "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-08-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01865617",
       "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
       "status": "COMPLETED",
       "last_update": "2022-05-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05020392",
       "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-07-25",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "BTK",
     "ibrutinib",
     "Imbruvica",
     "acalabrutinib",
     "Calquence",
     "zanubrutinib",
     "Brukinsa",
     "pirtobrutinib",
     "Jaypirca",
     "nemtabrutinib",
     "orelabrutinib"
    ]
   },
   "CD19": {
    "n": 88,
    "n_observational": 4,
    "n_active": 42,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT03676504",
      "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR",
      "status": "RECRUITING",
      "last_update": "2024-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04484012",
      "title": "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04545762",
      "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04792489",
      "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05098613",
      "title": "Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05281809",
      "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05365659",
      "title": "IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05432635",
      "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643742",
      "title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05910801",
      "title": "Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026319",
      "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06029309",
      "title": "Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06045910",
      "title": "A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-07-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06464861",
      "title": "Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482684",
      "title": "CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533579",
      "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06544265",
      "title": "SynKIR-310 for Relapsed/Refractory B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06553872",
      "title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06593145",
      "title": "CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003295",
      "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07077512",
      "title": "Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07673367",
      "title": "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07788118",
      "title": "A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7\u00d719-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816413",
      "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889408",
      "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00924326",
      "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00968760",
      "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01029366",
      "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2023-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01318317",
      "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01475058",
      "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
      "status": "COMPLETED",
      "last_update": "2017-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497184",
      "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01815749",
      "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01864889",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19",
      "status": "UNKNOWN",
      "last_update": "2016-01-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02051257",
      "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02081937",
      "title": "CART-19 Immunotherapy in Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2014-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02134262",
      "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
      "status": "UNKNOWN",
      "last_update": "2014-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02274506",
      "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells",
      "status": "WITHDRAWN",
      "last_update": "2020-01-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02454270",
      "title": "A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2018-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02601313",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02631044",
      "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
      "status": "COMPLETED",
      "last_update": "2024-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02650999",
      "title": "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02652910",
      "title": "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2019-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02669017",
      "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)",
      "status": "COMPLETED",
      "last_update": "2021-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02685670",
      "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-03-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721407",
      "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients",
      "status": "UNKNOWN",
      "last_update": "2017-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819583",
      "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-10-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02851589",
      "title": "Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02892695",
      "title": "PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097770",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
      "status": "COMPLETED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03185494",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
      "status": "UNKNOWN",
      "last_update": "2019-04-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571828",
      "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03579888",
      "title": "CD19-Specific T Cells Post AlloSCT",
      "status": "TERMINATED",
      "last_update": "2021-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685344",
      "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007029",
      "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04049513",
      "title": "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04082936",
      "title": "A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04184414",
      "title": "The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies",
      "status": "UNKNOWN",
      "last_update": "2019-12-03",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04450069",
      "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04488354",
      "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04718883",
      "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2023-11-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04844086",
      "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04880434",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05020392",
      "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2023-07-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05020678",
      "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249959",
      "title": "Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453396",
      "title": "Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05495464",
      "title": "A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665062",
      "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05788289",
      "title": "A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878184",
      "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05936229",
      "title": "Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy",
      "status": "WITHDRAWN",
      "last_update": "2024-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253663",
      "title": "Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06256484",
      "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06343376",
      "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06561425",
      "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024147",
      "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07412405",
      "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07569965",
      "title": "Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 48,
     "n_observational": 1,
     "n_active": 25,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT03676504",
       "title": "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR",
       "status": "RECRUITING",
       "last_update": "2024-07-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04186520",
       "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04484012",
       "title": "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-11-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04545762",
       "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04792489",
       "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-07-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05098613",
       "title": "Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients",
       "status": "RECRUITING",
       "last_update": "2026-07-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05281809",
       "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2025-01-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05432635",
       "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06026319",
       "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-03-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06464861",
       "title": "Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2025-02-07",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06482684",
       "title": "CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2024-07-01",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06593145",
       "title": "CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms",
       "status": "RECRUITING",
       "last_update": "2024-09-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07003295",
       "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07225439",
       "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07673367",
       "title": "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-08-17",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07788118",
       "title": "A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7\u00d719-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00924326",
       "title": "CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma",
       "status": "COMPLETED",
       "last_update": "2022-01-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01029366",
       "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",
       "status": "COMPLETED",
       "last_update": "2023-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01318317",
       "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01475058",
       "title": "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant",
       "status": "COMPLETED",
       "last_update": "2017-02-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01497184",
       "title": "Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",
       "status": "COMPLETED",
       "last_update": "2025-03-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01864889",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19",
       "status": "UNKNOWN",
       "last_update": "2016-01-28",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01865617",
       "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
       "status": "COMPLETED",
       "last_update": "2022-05-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02051257",
       "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-03-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02081937",
       "title": "CART-19 Immunotherapy in Mantle Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2014-03-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02134262",
       "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
       "status": "UNKNOWN",
       "last_update": "2014-11-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02153580",
       "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02274506",
       "title": "Infusion of Allogeneic, 3rd Party CD19-specific T Cells",
       "status": "WITHDRAWN",
       "last_update": "2020-01-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02650999",
       "title": "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas",
       "status": "COMPLETED",
       "last_update": "2021-07-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02652910",
       "title": "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2019-02-27",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02685670",
       "title": "Competitive Transfer of \u03b1CD19-TCRz-CD28 and \u03b1CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2017-03-16",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02721407",
       "title": "Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients",
       "status": "UNKNOWN",
       "last_update": "2017-03-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02819583",
       "title": "CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2016-10-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03097770",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
       "status": "COMPLETED",
       "last_update": "2020-09-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03185494",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",
       "status": "UNKNOWN",
       "last_update": "2019-04-17",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03579888",
       "title": "CD19-Specific T Cells Post AlloSCT",
       "status": "TERMINATED",
       "last_update": "2021-06-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04007029",
       "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04049513",
       "title": "ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2024-08-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04184414",
       "title": "The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies",
       "status": "UNKNOWN",
       "last_update": "2019-12-03",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04488354",
       "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
       "status": "COMPLETED",
       "last_update": "2026-04-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04718883",
       "title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2023-11-24",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04844086",
       "title": "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies",
       "status": "TERMINATED",
       "last_update": "2022-05-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05020392",
       "title": "Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma",
       "status": "UNKNOWN",
       "last_update": "2023-07-25",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05020678",
       "title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05665062",
       "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-07-10",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05936229",
       "title": "Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy",
       "status": "WITHDRAWN",
       "last_update": "2024-07-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06343376",
       "title": "Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies",
       "status": "TERMINATED",
       "last_update": "2025-08-03",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07412405",
       "title": "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-02-17",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD19",
     "brexucabtagene",
     "Tecartus",
     "lisocabtagene",
     "Breyanzi",
     "tafasitamab",
     "loncastuximab",
     "blinatumomab",
     "CD19 CAR"
    ]
   },
   "CD20": {
    "n": 288,
    "n_observational": 10,
    "n_active": 75,
    "n_withdrawn": 11,
    "trials": [
     {
      "nct": "NCT03523975",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04792489",
      "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855695",
      "title": "Avo In R/R And Previously Untreated MCL",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05245656",
      "title": "A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05833763",
      "title": "A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.",
      "status": "RECRUITING",
      "last_update": "2024-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861050",
      "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868395",
      "title": "Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05976763",
      "title": "Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05992597",
      "title": "ZR2 Sequential Immunochemotherapy for Newly Treated MCL",
      "status": "RECRUITING",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054776",
      "title": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084936",
      "title": "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136351",
      "title": "A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252675",
      "title": "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06263491",
      "title": "Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06357676",
      "title": "Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496308",
      "title": "Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2024-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06542250",
      "title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",
      "status": "RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06572618",
      "title": "Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06839053",
      "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846489",
      "title": "Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854003",
      "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Na\u00efve Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003295",
      "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07199296",
      "title": "Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07261163",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07272499",
      "title": "Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07285590",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07453095",
      "title": "Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07460362",
      "title": "Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07719556",
      "title": "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Na\u00efve Mantle Cell Lymphoma (MCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003280",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003356",
      "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003397",
      "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003963",
      "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004039",
      "title": "Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2015-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005089",
      "title": "S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005601",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007865",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012207",
      "title": "Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020943",
      "title": "Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022971",
      "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026182",
      "title": "Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028665",
      "title": "Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028717",
      "title": "Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2013-09-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040950",
      "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058227",
      "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00068315",
      "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073931",
      "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00076349",
      "title": "SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "COMPLETED",
      "last_update": "2014-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080886",
      "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00086944",
      "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101101",
      "title": "Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109967",
      "title": "CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110006",
      "title": "Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2010-06-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110071",
      "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00114738",
      "title": "EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119730",
      "title": "Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00151320",
      "title": "Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL",
      "status": "COMPLETED",
      "last_update": "2018-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00209209",
      "title": "Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL",
      "status": "UNKNOWN",
      "last_update": "2017-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00209222",
      "title": "Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL",
      "status": "UNKNOWN",
      "last_update": "2012-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00225212",
      "title": "Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244985",
      "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00261612",
      "title": "Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2006-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265928",
      "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2008-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00269113",
      "title": "A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274794",
      "title": "VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278161",
      "title": "Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278408",
      "title": "Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278421",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-03-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00285389",
      "title": "Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years",
      "status": "COMPLETED",
      "last_update": "2009-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00288067",
      "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00294632",
      "title": "Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295932",
      "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00299182",
      "title": "Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-09-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00310037",
      "title": "Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334438",
      "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00376961",
      "title": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397800",
      "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398372",
      "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",
      "status": "COMPLETED",
      "last_update": "2011-06-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00401817",
      "title": "Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416923",
      "title": "Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425802",
      "title": "Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00433537",
      "title": "Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00450801",
      "title": "R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00477412",
      "title": "Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00490529",
      "title": "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL",
      "status": "COMPLETED",
      "last_update": "2020-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00505232",
      "title": "Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)",
      "status": "COMPLETED",
      "last_update": "2012-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00525876",
      "title": "Non-Myeloablative Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2011-12-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00546377",
      "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00547534",
      "title": "Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00561756",
      "title": "Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00562978",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00581776",
      "title": "Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00581854",
      "title": "Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00586755",
      "title": "Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00596804",
      "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00601718",
      "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00607854",
      "title": "Safety of Ibritumomab Tiuxetan (Zevalin\u00ae) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)",
      "status": "COMPLETED",
      "last_update": "2016-10-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00609869",
      "title": "Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab",
      "status": "COMPLETED",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00621452",
      "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00625729",
      "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00633594",
      "title": "Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00641095",
      "title": "Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-10-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00656084",
      "title": "Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell",
      "status": "COMPLETED",
      "last_update": "2016-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695409",
      "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720876",
      "title": "Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00722137",
      "title": "Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-07-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726700",
      "title": "Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00764517",
      "title": "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00783367",
      "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787969",
      "title": "Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00794638",
      "title": "A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00856245",
      "title": "Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00863369",
      "title": "Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867529",
      "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00875667",
      "title": "A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2019-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877006",
      "title": "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877214",
      "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas",
      "status": "UNKNOWN",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00878254",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880815",
      "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891839",
      "title": "Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00921414",
      "title": "Mantel Cell Lymphoma Efficacy of Rituximab Maintenance",
      "status": "COMPLETED",
      "last_update": "2018-04-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00946374",
      "title": "Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2009-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00958256",
      "title": "Study of Bortezomib in Combination With Cyclophosphamide and Rituximab",
      "status": "COMPLETED",
      "last_update": "2015-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00963534",
      "title": "Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00968760",
      "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980395",
      "title": "Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00991211",
      "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992134",
      "title": "Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992446",
      "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01035463",
      "title": "Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01073163",
      "title": "Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2014-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01078142",
      "title": "Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01088048",
      "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118845",
      "title": "Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-07-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119794",
      "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",
      "status": "TERMINATED",
      "last_update": "2015-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184885",
      "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2025-05-04",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01221103",
      "title": "Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)",
      "status": "UNKNOWN",
      "last_update": "2011-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238146",
      "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2013-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01267812",
      "title": "Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01318317",
      "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01381692",
      "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01389427",
      "title": "Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).",
      "status": "COMPLETED",
      "last_update": "2017-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397591",
      "title": "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397825",
      "title": "MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine",
      "status": "COMPLETED",
      "last_update": "2018-03-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01410513",
      "title": "Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01412879",
      "title": "S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01415752",
      "title": "Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01419795",
      "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01439750",
      "title": "Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",
      "status": "UNKNOWN",
      "last_update": "2017-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01449344",
      "title": "Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL",
      "status": "UNKNOWN",
      "last_update": "2017-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01457144",
      "title": "Study of Mantle Cell Lymphoma Treatment by RiBVD",
      "status": "COMPLETED",
      "last_update": "2016-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472562",
      "title": "Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497275",
      "title": "Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01527149",
      "title": "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599949",
      "title": "A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy",
      "status": "COMPLETED",
      "last_update": "2016-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01665768",
      "title": "Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01678417",
      "title": "131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01695941",
      "title": "Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01718691",
      "title": "Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01735604",
      "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2015-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01737177",
      "title": "Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL",
      "status": "COMPLETED",
      "last_update": "2018-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744912",
      "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776840",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01880567",
      "title": "Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01933711",
      "title": "Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01996865",
      "title": "Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213913",
      "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257242",
      "title": "Vincristine Sulfate Liposome Injection (Marqibo\u00ae), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02281279",
      "title": "Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339922",
      "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02427620",
      "title": "Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460276",
      "title": "A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02483000",
      "title": "Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-11-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02558816",
      "title": "A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02632396",
      "title": "Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission",
      "status": "UNKNOWN",
      "last_update": "2023-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02657447",
      "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)",
      "status": "WITHDRAWN",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02682641",
      "title": "Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717624",
      "title": "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02728531",
      "title": "Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02733042",
      "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02735876",
      "title": "A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736617",
      "title": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858258",
      "title": "ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858804",
      "title": "EDOCH Alternating With DHAP for New Diagnosed Younger MCL",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02896582",
      "title": "Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance",
      "status": "COMPLETED",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02924402",
      "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983097",
      "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019640",
      "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097770",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
      "status": "COMPLETED",
      "last_update": "2020-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03229382",
      "title": "Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse",
      "status": "TERMINATED",
      "last_update": "2023-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03232307",
      "title": "Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2019-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267433",
      "title": "Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277729",
      "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03295240",
      "title": "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311126",
      "title": "Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03440567",
      "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03505944",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03579927",
      "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03623373",
      "title": "Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03710772",
      "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03824483",
      "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834688",
      "title": "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03863184",
      "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872180",
      "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04002297",
      "title": "A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04007029",
      "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04047797",
      "title": "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04115631",
      "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04176913",
      "title": "Study of LUCAR-20S in Patients With R/R NHL",
      "status": "TERMINATED",
      "last_update": "2022-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626791",
      "title": "Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703686",
      "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04735471",
      "title": "A Phase 1 Study of ADI-001 in B Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736914",
      "title": "Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04765111",
      "title": "Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802590",
      "title": "Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04918940",
      "title": "Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05003141",
      "title": "PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2022-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025423",
      "title": "Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05051891",
      "title": "A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-na\u0457ve Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076097",
      "title": "A Study of OLR in First-line Treatment of Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097443",
      "title": "Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05214183",
      "title": "Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249959",
      "title": "Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05360238",
      "title": "Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL",
      "status": "TERMINATED",
      "last_update": "2024-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05504603",
      "title": "Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564052",
      "title": "A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05934097",
      "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05951959",
      "title": "A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06192888",
      "title": "A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324994",
      "title": "Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427213",
      "title": "This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504199",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522386",
      "title": "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06656221",
      "title": "A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024147",
      "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07206264",
      "title": "Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07444710",
      "title": "Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548255",
      "title": "The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07569965",
      "title": "Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07578077",
      "title": "Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07748364",
      "title": "Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07799220",
      "title": "A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 17,
     "n_observational": 1,
     "n_active": 8,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT04186520",
       "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04792489",
       "title": "DALY II USA/ MB-CART2019.1 for DLBCL",
       "status": "RECRUITING",
       "last_update": "2026-07-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07003295",
       "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07225439",
       "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07453095",
       "title": "Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-06-25",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00176475",
       "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
       "status": "TERMINATED",
       "last_update": "2013-09-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00521261",
       "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2014-03-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00621452",
       "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",
       "status": "COMPLETED",
       "last_update": "2014-08-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01318317",
       "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01735604",
       "title": "Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",
       "status": "UNKNOWN",
       "last_update": "2015-09-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03019640",
       "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",
       "status": "COMPLETED",
       "last_update": "2023-02-16",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03019666",
       "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
       "status": "COMPLETED",
       "last_update": "2022-11-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03097770",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",
       "status": "COMPLETED",
       "last_update": "2020-09-02",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03277729",
       "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03579927",
       "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2020-01-29",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04007029",
       "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04703686",
       "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
       "status": "COMPLETED",
       "last_update": "2026-03-16",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD20",
     "rituximab",
     "obinutuzumab",
     "glofitamab",
     "mosunetuzumab",
     "epcoritamab",
     "odronextamab",
     "CD20xCD3"
    ]
   },
   "BCL-2": {
    "n": 59,
    "n_observational": 3,
    "n_active": 36,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03523975",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855695",
      "title": "Avo In R/R And Previously Untreated MCL",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05529069",
      "title": "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861050",
      "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05910801",
      "title": "Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496308",
      "title": "Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2024-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06697184",
      "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742996",
      "title": "A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06839053",
      "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854003",
      "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Na\u00efve Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07272499",
      "title": "Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07341191",
      "title": "Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07609862",
      "title": "A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07719556",
      "title": "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Na\u00efve Mantle Cell Lymphoma (MCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060112",
      "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00086944",
      "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419560",
      "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL",
      "status": "COMPLETED",
      "last_update": "2022-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02471391",
      "title": "ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)",
      "status": "UNKNOWN",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02558816",
      "title": "A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717624",
      "title": "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03112174",
      "title": "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03295240",
      "title": "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03505944",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03567876",
      "title": "Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL",
      "status": "COMPLETED",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03710772",
      "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03824483",
      "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834688",
      "title": "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872180",
      "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03946878",
      "title": "Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04072458",
      "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04477486",
      "title": "Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802590",
      "title": "Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04939272",
      "title": "Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04990778",
      "title": "Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "status": "COMPLETED",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025423",
      "title": "Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05471843",
      "title": "Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864742",
      "title": "Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (\u00b1 Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05951959",
      "title": "A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06106841",
      "title": "TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "TERMINATED",
      "last_update": "2025-12-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324994",
      "title": "Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522386",
      "title": "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548255",
      "title": "The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07684950",
      "title": "Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07799220",
      "title": "A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07341191",
       "title": "Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "BCL-2",
     "BCL2",
     "venetoclax",
     "sonrotoclax",
     "lisaftoclax"
    ]
   },
   "CD79b": {
    "n": 6,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04491370",
      "title": "Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868395",
      "title": "Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026319",
      "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913103",
      "title": "Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2021-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT06026319",
       "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-03-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD79b",
     "polatuzumab"
    ]
   },
   "ROR1": {
    "n": 9,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT02706392",
      "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088878",
      "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03833180",
      "title": "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)",
      "status": "COMPLETED",
      "last_update": "2024-01-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04763083",
      "title": "First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies",
      "status": "UNKNOWN",
      "last_update": "2023-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05431179",
      "title": "A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-04-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05458297",
      "title": "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05588440",
      "title": "A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-12-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05694364",
      "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07697339",
      "title": "HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02706392",
       "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies",
       "status": "TERMINATED",
       "last_update": "2022-08-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05694364",
       "title": "Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies",
       "status": "COMPLETED",
       "last_update": "2026-02-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "ROR1",
     "zilovertamab",
     "cirmtuzumab"
    ]
   },
   "CDK4/6": {
    "n": 6,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00420056",
      "title": "An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01111188",
      "title": "Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01739309",
      "title": "Study of LY2835219 for Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159755",
      "title": "Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02745769",
      "title": "A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents",
      "status": "COMPLETED",
      "last_update": "2019-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03478514",
      "title": "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CDK4",
     "palbociclib",
     "abemaciclib"
    ]
   },
   "BTK degrader": {
    "n": 7,
    "n_observational": 0,
    "n_active": 7,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05006716",
      "title": "A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05294731",
      "title": "Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05780034",
      "title": "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07684950",
      "title": "Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BTK degrader",
     "NX-2127",
     "NX-5948",
     "BGB-16673"
    ]
   }
  },
  "by_drug": {
   "ACALABRUTINIB": {
    "n": 39,
    "n_observational": 2,
    "n_active": 27,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04484012",
      "title": "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855695",
      "title": "Avo In R/R And Previously Untreated MCL",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643235",
      "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054776",
      "title": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06564038",
      "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846489",
      "title": "Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07029737",
      "title": "A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07377578",
      "title": "A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213926",
      "title": "An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02328014",
      "title": "Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-12-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02362035",
      "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717624",
      "title": "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02735876",
      "title": "A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02972840",
      "title": "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03219047",
      "title": "Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03623373",
      "title": "Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03863184",
      "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03932331",
      "title": "Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03946878",
      "title": "Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04115631",
      "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189757",
      "title": "Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04402138",
      "title": "Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04564040",
      "title": "A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole",
      "status": "COMPLETED",
      "last_update": "2020-12-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04566887",
      "title": "Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626791",
      "title": "Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04662255",
      "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04716075",
      "title": "Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)",
      "status": "COMPLETED",
      "last_update": "2025-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04765111",
      "title": "Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04783415",
      "title": "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04930536",
      "title": "Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-11-22",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05004064",
      "title": "Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05214183",
      "title": "Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05495464",
      "title": "A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05951959",
      "title": "A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "APG-2575": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07272499",
      "title": "Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AXICABTAGENE CILOLEUCEL": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02601313",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BLINATUMOMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BREXUCABTAGENE AUTOLEUCEL": {
    "n": 7,
    "n_observational": 2,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06482684",
      "title": "CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06553872",
      "title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07673367",
      "title": "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02601313",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04880434",
      "title": "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)",
      "status": "COMPLETED",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05495464",
      "title": "A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06253663",
      "title": "Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DENINTUZUMAB MAFODOTIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01786135",
      "title": "A Safety Study of SGN-CD19A for B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPCORITAMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPRENETAPOPT": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04990778",
      "title": "Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GLOFITAMAB": {
    "n": 15,
    "n_observational": 0,
    "n_active": 14,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05833763",
      "title": "A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.",
      "status": "RECRUITING",
      "last_update": "2024-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861050",
      "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054776",
      "title": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084936",
      "title": "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252675",
      "title": "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06357676",
      "title": "Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003295",
      "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07453095",
      "title": "Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07460362",
      "title": "Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703686",
      "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06192888",
      "title": "A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06656221",
      "title": "A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07444710",
      "title": "Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07748364",
      "title": "Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IBRUTINIB": {
    "n": 78,
    "n_observational": 12,
    "n_active": 25,
    "n_withdrawn": 7,
    "trials": [
     {
      "nct": "NCT01804686",
      "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643235",
      "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06357676",
      "title": "Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06482684",
      "title": "CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07377578",
      "title": "A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849654",
      "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01109069",
      "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2020-05-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01236391",
      "title": "Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2015-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599949",
      "title": "A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy",
      "status": "COMPLETED",
      "last_update": "2016-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01646021",
      "title": "Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy",
      "status": "COMPLETED",
      "last_update": "2018-01-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776840",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "status": "COMPLETED",
      "last_update": "2022-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01880567",
      "title": "Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02013128",
      "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "status": "TERMINATED",
      "last_update": "2015-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159755",
      "title": "Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02169180",
      "title": "Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02242097",
      "title": "Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02268851",
      "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02269085",
      "title": "Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02303392",
      "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02356458",
      "title": "Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381080",
      "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",
      "status": "COMPLETED",
      "last_update": "2017-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419560",
      "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL",
      "status": "COMPLETED",
      "last_update": "2022-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02427620",
      "title": "Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446236",
      "title": "Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02455297",
      "title": "Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "TERMINATED",
      "last_update": "2017-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460276",
      "title": "A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02471391",
      "title": "ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)",
      "status": "UNKNOWN",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02558816",
      "title": "A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02682641",
      "title": "Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02733042",
      "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02735876",
      "title": "A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736617",
      "title": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02743546",
      "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02756247",
      "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858258",
      "title": "ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02869633",
      "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2023-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02927964",
      "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02991638",
      "title": "Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers",
      "status": "UNKNOWN",
      "last_update": "2018-04-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088878",
      "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03112174",
      "title": "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03153202",
      "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190330",
      "title": "A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03219047",
      "title": "Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03232307",
      "title": "Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2019-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03235544",
      "title": "A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor",
      "status": "COMPLETED",
      "last_update": "2025-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03282396",
      "title": "Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03295240",
      "title": "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323151",
      "title": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03440567",
      "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03478514",
      "title": "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03617484",
      "title": "Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03710772",
      "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03877055",
      "title": "A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-12-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03939182",
      "title": "Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043845",
      "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189757",
      "title": "Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234061",
      "title": "Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04477486",
      "title": "Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04662255",
      "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665115",
      "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)",
      "status": "WITHDRAWN",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802590",
      "title": "Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05214183",
      "title": "Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05431179",
      "title": "A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-04-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564052",
      "title": "A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864742",
      "title": "Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (\u00b1 Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LFB-R603": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04783415",
      "title": "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LISOCABTAGENE MARALEUCEL": {
    "n": 1,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02631044",
      "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
      "status": "COMPLETED",
      "last_update": "2024-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LONCASTUXIMAB TESIRINE": {
    "n": 6,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02669017",
      "title": "Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)",
      "status": "COMPLETED",
      "last_update": "2021-05-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03684694",
      "title": "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685344",
      "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
      "status": "TERMINATED",
      "last_update": "2021-10-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04082936",
      "title": "A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-07-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249959",
      "title": "Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05453396",
      "title": "Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVITOCLAX": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00406809",
      "title": "A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-08-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864742",
      "title": "Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (\u00b1 Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NAVTEMADLIN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02825836",
      "title": "Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Na\u00efve and R/R CLL/SLL Subjects",
      "status": "UNKNOWN",
      "last_update": "2023-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBATOCLAX": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00407303",
      "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2016-07-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00538187",
      "title": "Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238146",
      "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2013-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBINUTUZUMAB": {
    "n": 33,
    "n_observational": 0,
    "n_active": 23,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04855695",
      "title": "Avo In R/R And Previously Untreated MCL",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05833763",
      "title": "A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.",
      "status": "RECRUITING",
      "last_update": "2024-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861050",
      "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054776",
      "title": "Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084936",
      "title": "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252675",
      "title": "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06357676",
      "title": "Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07003295",
      "title": "Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07261163",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07453095",
      "title": "Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07719556",
      "title": "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Na\u00efve Mantle Cell Lymphoma (MCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02558816",
      "title": "A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736617",
      "title": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02896582",
      "title": "Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance",
      "status": "COMPLETED",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03229382",
      "title": "Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse",
      "status": "TERMINATED",
      "last_update": "2023-08-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311126",
      "title": "Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03824483",
      "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03863184",
      "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872180",
      "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04703686",
      "title": "Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04918940",
      "title": "Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06192888",
      "title": "A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324994",
      "title": "Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427213",
      "title": "This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504199",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06656221",
      "title": "A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548255",
      "title": "The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07799220",
      "title": "A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBLIMERSEN": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060112",
      "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00086944",
      "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OCARATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ODRONEXTAMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OFATUMUMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01088048",
      "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119794",
      "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",
      "status": "TERMINATED",
      "last_update": "2015-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01221103",
      "title": "Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)",
      "status": "UNKNOWN",
      "last_update": "2011-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397591",
      "title": "Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-07-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01437709",
      "title": "Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2025-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01527149",
      "title": "Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ORELABRUTINIB": {
    "n": 14,
    "n_observational": 0,
    "n_active": 10,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06363994",
      "title": "A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL",
      "status": "RECRUITING",
      "last_update": "2024-12-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496308",
      "title": "Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2024-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07199296",
      "title": "Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07257510",
      "title": "Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07272499",
      "title": "Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07377578",
      "title": "A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07719556",
      "title": "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Na\u00efve Mantle Cell Lymphoma (MCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05051891",
      "title": "A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-na\u0457ve Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076097",
      "title": "A Study of OLR in First-line Treatment of Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097443",
      "title": "Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05978739",
      "title": "Evaluating Different Doses of Orelabrutinib in MCL",
      "status": "COMPLETED",
      "last_update": "2026-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06656221",
      "title": "A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07206264",
      "title": "Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07784101",
      "title": "A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PALBOCICLIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00420056",
      "title": "An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2015-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01111188",
      "title": "Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-06-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159755",
      "title": "Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03478514",
      "title": "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PIRTOBRUTINIB": {
    "n": 18,
    "n_observational": 1,
    "n_active": 15,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05529069",
      "title": "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05602363",
      "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643235",
      "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05833763",
      "title": "A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.",
      "status": "RECRUITING",
      "last_update": "2024-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05990465",
      "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06252675",
      "title": "Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06263491",
      "title": "Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06553872",
      "title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL",
      "status": "RECRUITING",
      "last_update": "2026-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07285590",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04662255",
      "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04849416",
      "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "status": "COMPLETED",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522386",
      "title": "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07207785",
      "title": "PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07684950",
      "title": "Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07784101",
      "title": "A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RITUXIMAB": {
    "n": 195,
    "n_observational": 5,
    "n_active": 34,
    "n_withdrawn": 9,
    "trials": [
     {
      "nct": "NCT03523975",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05245656",
      "title": "A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868395",
      "title": "Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-05-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05976763",
      "title": "Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05992597",
      "title": "ZR2 Sequential Immunochemotherapy for Newly Treated MCL",
      "status": "RECRUITING",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084936",
      "title": "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136351",
      "title": "A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06263491",
      "title": "Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496308",
      "title": "Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2024-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06572618",
      "title": "Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06846489",
      "title": "Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854003",
      "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Na\u00efve Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07199296",
      "title": "Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07272499",
      "title": "Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07285590",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003280",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003356",
      "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003397",
      "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003963",
      "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005089",
      "title": "S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005601",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007865",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00020943",
      "title": "Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00022971",
      "title": "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2019-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026182",
      "title": "Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028665",
      "title": "Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040950",
      "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058227",
      "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00068315",
      "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00076349",
      "title": "SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)",
      "status": "COMPLETED",
      "last_update": "2014-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00086944",
      "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101101",
      "title": "Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00109967",
      "title": "CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110006",
      "title": "Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2010-06-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00114738",
      "title": "EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119730",
      "title": "Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00151320",
      "title": "Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL",
      "status": "COMPLETED",
      "last_update": "2018-06-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00209209",
      "title": "Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL",
      "status": "UNKNOWN",
      "last_update": "2017-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00209222",
      "title": "Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL",
      "status": "UNKNOWN",
      "last_update": "2012-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00225212",
      "title": "Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244985",
      "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00261612",
      "title": "Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2006-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265928",
      "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2008-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00269113",
      "title": "A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274794",
      "title": "VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278161",
      "title": "Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00285389",
      "title": "Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years",
      "status": "COMPLETED",
      "last_update": "2009-02-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00288067",
      "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00294632",
      "title": "Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295932",
      "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00299182",
      "title": "Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-09-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00310037",
      "title": "Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334438",
      "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00376961",
      "title": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397800",
      "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398372",
      "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",
      "status": "COMPLETED",
      "last_update": "2011-06-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00401817",
      "title": "Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416923",
      "title": "Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425802",
      "title": "Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00433537",
      "title": "Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00450801",
      "title": "R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-11-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00490529",
      "title": "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL",
      "status": "COMPLETED",
      "last_update": "2020-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00525876",
      "title": "Non-Myeloablative Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2011-12-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00546377",
      "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00547534",
      "title": "Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00581776",
      "title": "Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00581854",
      "title": "Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00586755",
      "title": "Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00601718",
      "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00609869",
      "title": "Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab",
      "status": "COMPLETED",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00633594",
      "title": "Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-01-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00641095",
      "title": "Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-10-31",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00656084",
      "title": "Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell",
      "status": "COMPLETED",
      "last_update": "2016-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720876",
      "title": "Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00722137",
      "title": "Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-07-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00764517",
      "title": "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00787969",
      "title": "Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00794638",
      "title": "A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00856245",
      "title": "Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00863369",
      "title": "Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00875667",
      "title": "A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2019-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877006",
      "title": "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877214",
      "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas",
      "status": "UNKNOWN",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00878254",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880815",
      "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891839",
      "title": "Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00921414",
      "title": "Mantel Cell Lymphoma Efficacy of Rituximab Maintenance",
      "status": "COMPLETED",
      "last_update": "2018-04-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00946374",
      "title": "Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2009-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00958256",
      "title": "Study of Bortezomib in Combination With Cyclophosphamide and Rituximab",
      "status": "COMPLETED",
      "last_update": "2015-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00963534",
      "title": "Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2018-03-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00968760",
      "title": "CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980395",
      "title": "Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00991211",
      "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992134",
      "title": "Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992446",
      "title": "Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01035463",
      "title": "Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01073163",
      "title": "Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2014-04-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01078142",
      "title": "Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01088048",
      "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2021-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118845",
      "title": "Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-07-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119794",
      "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",
      "status": "TERMINATED",
      "last_update": "2015-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184885",
      "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2025-05-04",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238146",
      "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2013-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01267812",
      "title": "Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01318317",
      "title": "Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01389427",
      "title": "Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).",
      "status": "COMPLETED",
      "last_update": "2017-03-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01397825",
      "title": "MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine",
      "status": "COMPLETED",
      "last_update": "2018-03-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01410513",
      "title": "Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2016-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01412879",
      "title": "S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01415752",
      "title": "Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01439750",
      "title": "Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",
      "status": "UNKNOWN",
      "last_update": "2017-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01449344",
      "title": "Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL",
      "status": "UNKNOWN",
      "last_update": "2017-03-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01457144",
      "title": "Study of Mantle Cell Lymphoma Treatment by RiBVD",
      "status": "COMPLETED",
      "last_update": "2016-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472562",
      "title": "Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497275",
      "title": "Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599949",
      "title": "A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy",
      "status": "COMPLETED",
      "last_update": "2016-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01665768",
      "title": "Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01678417",
      "title": "131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01695941",
      "title": "Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01718691",
      "title": "Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01737177",
      "title": "Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL",
      "status": "COMPLETED",
      "last_update": "2018-03-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01776840",
      "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01880567",
      "title": "Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01933711",
      "title": "Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01996865",
      "title": "Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213913",
      "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02281279",
      "title": "Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460276",
      "title": "A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02632396",
      "title": "Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission",
      "status": "UNKNOWN",
      "last_update": "2023-05-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02657447",
      "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)",
      "status": "WITHDRAWN",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02682641",
      "title": "Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717624",
      "title": "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02728531",
      "title": "Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02733042",
      "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02735876",
      "title": "A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-05-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858258",
      "title": "ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2017-12-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02858804",
      "title": "EDOCH Alternating With DHAP for New Diagnosed Younger MCL",
      "status": "COMPLETED",
      "last_update": "2026-02-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983097",
      "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03232307",
      "title": "Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2019-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267433",
      "title": "Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03295240",
      "title": "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311126",
      "title": "Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03505944",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03579927",
      "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03623373",
      "title": "Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834688",
      "title": "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03863184",
      "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04002297",
      "title": "A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04047797",
      "title": "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04115631",
      "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626791",
      "title": "Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736914",
      "title": "Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04765111",
      "title": "Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04918940",
      "title": "Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025423",
      "title": "Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05051891",
      "title": "A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-na\u0457ve Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05076097",
      "title": "A Study of OLR in First-line Treatment of Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05097443",
      "title": "Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05249959",
      "title": "Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05504603",
      "title": "Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564052",
      "title": "A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05934097",
      "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05951959",
      "title": "A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522386",
      "title": "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07444710",
      "title": "Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07578077",
      "title": "Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TAFASITAMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05910801",
      "title": "Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06029309",
      "title": "Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05788289",
      "title": "A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIRABRUTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TISAGENLECLEUCEL": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04234061",
      "title": "Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOSITUMOMAB": {
    "n": 6,
    "n_observational": 2,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00022945",
      "title": "Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2005-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073931",
      "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110071",
      "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992992",
      "title": "Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01484093",
      "title": "Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOSITUMOMAB 131I": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   },
   "UBLITUXIMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01744912",
      "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02013128",
      "title": "Ublituximab + Ibrutinib in Select B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02793583",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-07-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04692155",
      "title": "Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)",
      "status": "TERMINATED",
      "last_update": "2023-09-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04783415",
      "title": "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VECABRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VELTUZUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT00596804",
      "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101581",
      "title": "Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL",
      "status": "WITHDRAWN",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VENETOCLAX": {
    "n": 39,
    "n_observational": 2,
    "n_active": 21,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03523975",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04855695",
      "title": "Avo In R/R And Previously Untreated MCL",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05529069",
      "title": "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861050",
      "title": "Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05910801",
      "title": "Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496308",
      "title": "Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment",
      "status": "RECRUITING",
      "last_update": "2024-07-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07719556",
      "title": "Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Na\u00efve Mantle Cell Lymphoma (MCL)",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419560",
      "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL",
      "status": "COMPLETED",
      "last_update": "2022-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02471391",
      "title": "ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)",
      "status": "UNKNOWN",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02558816",
      "title": "A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2026-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02717624",
      "title": "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03112174",
      "title": "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2025-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03295240",
      "title": "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03505944",
      "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-10-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03567876",
      "title": "Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL",
      "status": "COMPLETED",
      "last_update": "2025-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03710772",
      "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03824483",
      "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03834688",
      "title": "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age",
      "status": "COMPLETED",
      "last_update": "2025-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872180",
      "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03946878",
      "title": "Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04419389",
      "title": "APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)",
      "status": "TERMINATED",
      "last_update": "2025-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04477486",
      "title": "Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802590",
      "title": "Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04939272",
      "title": "Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04990778",
      "title": "Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025423",
      "title": "Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05864742",
      "title": "Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (\u00b1 Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05951959",
      "title": "A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na\u00efve Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06324994",
      "title": "Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06522386",
      "title": "GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": {
    "n": 18,
    "n_observational": 2,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00038623",
      "title": "Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070018",
      "title": "S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00070447",
      "title": "Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334438",
      "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392691",
      "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397800",
      "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00505232",
      "title": "Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)",
      "status": "COMPLETED",
      "last_update": "2012-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00514475",
      "title": "Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00562978",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2021-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695409",
      "title": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497275",
      "title": "Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01686165",
      "title": "Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL",
      "status": "COMPLETED",
      "last_update": "2018-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANUBRUTINIB": {
    "n": 35,
    "n_observational": 3,
    "n_active": 25,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05635162",
      "title": "Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643235",
      "title": "Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05976763",
      "title": "Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06029309",
      "title": "Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06136351",
      "title": "A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06341556",
      "title": "A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06558604",
      "title": "Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06697184",
      "title": "A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.",
      "status": "RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06742996",
      "title": "A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06839053",
      "title": "Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06854003",
      "title": "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Na\u00efve Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07261163",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07341191",
      "title": "Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07377578",
      "title": "A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03206970",
      "title": "Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03824483",
      "title": "Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04002297",
      "title": "A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172246",
      "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282018",
      "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04624958",
      "title": "Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04662255",
      "title": "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736914",
      "title": "Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05164770",
      "title": "Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-12-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05504603",
      "title": "Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06255704",
      "title": "A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06427213",
      "title": "This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504199",
      "title": "Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07548255",
      "title": "The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07799220",
      "title": "A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}